Med-IQ cardiology
@med-iqcardiology.bsky.social
Your go-to source for cardiology education. Sharing the latest in cardiovascular medicine, guidelines and CME. @med-iq.bsky.social is a leading provider of CME-accredited content, dedicated to better healthcare for all.
@med-iq.bsky.social
#RiskTipTuesday: #Debriefing breaks down silos, strengthens teams, and leads to safer care.
Learn about practical strategies for building a culture of safety in our full blog: link.med-iq.com/2wmEKs
#PatientSafety #TeamPerformance #HealthcareLeadership
#RiskTipTuesday: #Debriefing breaks down silos, strengthens teams, and leads to safer care.
Learn about practical strategies for building a culture of safety in our full blog: link.med-iq.com/2wmEKs
#PatientSafety #TeamPerformance #HealthcareLeadership
November 18, 2025 at 1:41 PM
@med-iq.bsky.social
#RiskTipTuesday: #Debriefing breaks down silos, strengthens teams, and leads to safer care.
Learn about practical strategies for building a culture of safety in our full blog: link.med-iq.com/2wmEKs
#PatientSafety #TeamPerformance #HealthcareLeadership
#RiskTipTuesday: #Debriefing breaks down silos, strengthens teams, and leads to safer care.
Learn about practical strategies for building a culture of safety in our full blog: link.med-iq.com/2wmEKs
#PatientSafety #TeamPerformance #HealthcareLeadership
Thank you to Dr. Ahmad Masri for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #AHA25. Check out this thread for highlights.
#CardioBluesky #MedIQAHA25
#CardioBluesky #MedIQAHA25
November 12, 2025 at 5:35 PM
Thank you to Dr. Ahmad Masri for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #AHA25. Check out this thread for highlights.
#CardioBluesky #MedIQAHA25
#CardioBluesky #MedIQAHA25
1/22 In this #CME, Dr. Milind Desai provides guidance on #oHCM, including making the diagnosis, staying up-to-date on cardiac myosin inhibitors, and addressing patients’ concerns.
Get credit: link.med-iq.com/oXPP2o
Get credit: link.med-iq.com/oXPP2o
November 10, 2025 at 4:13 PM
1/22 In this #CME, Dr. Milind Desai provides guidance on #oHCM, including making the diagnosis, staying up-to-date on cardiac myosin inhibitors, and addressing patients’ concerns.
Get credit: link.med-iq.com/oXPP2o
Get credit: link.med-iq.com/oXPP2o
1/22 In this #CME #MedX, Matthew W. Martinez, MD, FACC, provides guidance for managing HCM, from symptoms to diagnosis and treatment, and explores when oHCM may be hiding in plain sight.
Participate for credit: link.med-iq.com/7mpkl9
Supported by an educational grant from Bristol Myers Squibb.
Participate for credit: link.med-iq.com/7mpkl9
Supported by an educational grant from Bristol Myers Squibb.
September 30, 2025 at 5:42 PM
1/22 In this #CME #MedX, Matthew W. Martinez, MD, FACC, provides guidance for managing HCM, from symptoms to diagnosis and treatment, and explores when oHCM may be hiding in plain sight.
Participate for credit: link.med-iq.com/7mpkl9
Supported by an educational grant from Bristol Myers Squibb.
Participate for credit: link.med-iq.com/7mpkl9
Supported by an educational grant from Bristol Myers Squibb.
Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025.
Check out this thread for highlights.
#MedIQHFSA2025
Check out this thread for highlights.
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025.
Check out this thread for highlights.
#MedIQHFSA2025
Check out this thread for highlights.
#MedIQHFSA2025
Thank you to Ahmad Masri, MD, for his live updates on ATTR-CM from #ESC2025. Check out this thread for highlights!
#Transthyretinamyloidcardiomyopathy #Cardiomyopathy #Amyloidosis #MedIQESCCongress #ESCCongress #CardioSky #MedSky
#Transthyretinamyloidcardiomyopathy #Cardiomyopathy #Amyloidosis #MedIQESCCongress #ESCCongress #CardioSky #MedSky
September 5, 2025 at 3:51 PM
Thank you to Ahmad Masri, MD, for his live updates on ATTR-CM from #ESC2025. Check out this thread for highlights!
#Transthyretinamyloidcardiomyopathy #Cardiomyopathy #Amyloidosis #MedIQESCCongress #ESCCongress #CardioSky #MedSky
#Transthyretinamyloidcardiomyopathy #Cardiomyopathy #Amyloidosis #MedIQESCCongress #ESCCongress #CardioSky #MedSky
Location, location, location! New in European Heart Journal: Sex-dependent body fat deposition patterns influence the pace of #CV ageing, w/estrogen providing protective effects. Read here: doi.org/10.1093/eurh... #EHJ #CardioSky #MedSky
August 25, 2025 at 5:09 PM
Location, location, location! New in European Heart Journal: Sex-dependent body fat deposition patterns influence the pace of #CV ageing, w/estrogen providing protective effects. Read here: doi.org/10.1093/eurh... #EHJ #CardioSky #MedSky
🆕 ACC Launches HCM Digital Registry
The ACC aims to accelerate insights into #cvHCM & expand equitable access to treatment. CONNECT-HCM digital registry aims to ↗️ understanding & improve care for what is one of the most common genetic #CVDs. More: https://bit.ly/471eUiI
#CardioSky #MedSky
The ACC aims to accelerate insights into #cvHCM & expand equitable access to treatment. CONNECT-HCM digital registry aims to ↗️ understanding & improve care for what is one of the most common genetic #CVDs. More: https://bit.ly/471eUiI
#CardioSky #MedSky
August 20, 2025 at 10:07 PM
New AHA/ACC #hypertension guidelines! Key updates:
• Use of PREVENT calculator (no race-based recs)
• Screen for hyperaldosteronism in all pts w/resistant HTN
• Push for single-pill combos, home BP monitoring, multidisciplinary mgmt & community care
• Use of PREVENT calculator (no race-based recs)
• Screen for hyperaldosteronism in all pts w/resistant HTN
• Push for single-pill combos, home BP monitoring, multidisciplinary mgmt & community care
The new AHA/ACC/Multisociety #ClinicalGuideline on high #bloodpressure provides updated recommendations for clinicians on the prevention, detection, evaluation, and management of high blood pressure in adults.
Get the details in #JACC: www.jacc.org/doi/10.1016/...
#Hypertension #CardioSky #MedSky
Get the details in #JACC: www.jacc.org/doi/10.1016/...
#Hypertension #CardioSky #MedSky
August 18, 2025 at 3:58 PM
New AHA/ACC #hypertension guidelines! Key updates:
• Use of PREVENT calculator (no race-based recs)
• Screen for hyperaldosteronism in all pts w/resistant HTN
• Push for single-pill combos, home BP monitoring, multidisciplinary mgmt & community care
• Use of PREVENT calculator (no race-based recs)
• Screen for hyperaldosteronism in all pts w/resistant HTN
• Push for single-pill combos, home BP monitoring, multidisciplinary mgmt & community care
Ultraprocessed foods are connected with cardiometabolic disease, chronic illness, mortality risk. What are they exactly & are they all bad? New AHA guidance provides some insight, nuance. Helpful framing or mixed messaging?
Read more here: www.ahajournals.org/doi/full/10.... #CardioSky
Read more here: www.ahajournals.org/doi/full/10.... #CardioSky
August 12, 2025 at 5:50 PM
Ultraprocessed foods are connected with cardiometabolic disease, chronic illness, mortality risk. What are they exactly & are they all bad? New AHA guidance provides some insight, nuance. Helpful framing or mixed messaging?
Read more here: www.ahajournals.org/doi/full/10.... #CardioSky
Read more here: www.ahajournals.org/doi/full/10.... #CardioSky
ICYMI: 10,000 steps/day goal gets a rethink in
@thelancetph.bsky.social. Clinically meaningful reduction in CVD incidence & death associated w/ just 7,000 steps/day is a much more realistic target for some patients!
www.thelancet.com/journals/lan...
#Cardiosky #Medsky
@thelancetph.bsky.social. Clinically meaningful reduction in CVD incidence & death associated w/ just 7,000 steps/day is a much more realistic target for some patients!
www.thelancet.com/journals/lan...
#Cardiosky #Medsky
Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis
Although 10 000 steps per day can still be a viable target for those who are more
active, 7000 steps per day is associated with clinically meaningful improvements in
health outcomes and might be a mor...
www.thelancet.com
August 4, 2025 at 4:05 PM
ICYMI: 10,000 steps/day goal gets a rethink in
@thelancetph.bsky.social. Clinically meaningful reduction in CVD incidence & death associated w/ just 7,000 steps/day is a much more realistic target for some patients!
www.thelancet.com/journals/lan...
#Cardiosky #Medsky
@thelancetph.bsky.social. Clinically meaningful reduction in CVD incidence & death associated w/ just 7,000 steps/day is a much more realistic target for some patients!
www.thelancet.com/journals/lan...
#Cardiosky #Medsky
2° analysis of 1yr tirzepatide tx for obesity & #HFpEF in SUMMIT trial:
• Pts w/⬆️baseline BMI: greater ⬆️6MWD vs placebo
• Pts w/⬆️weight loss w/tx: greater ⬆️exercise capacity, sx burden
Incretin tx is an important part of HFpEF mgmt! www.jacc.org/doi/10.1016/... #CardioSky #MedSky
• Pts w/⬆️baseline BMI: greater ⬆️6MWD vs placebo
• Pts w/⬆️weight loss w/tx: greater ⬆️exercise capacity, sx burden
Incretin tx is an important part of HFpEF mgmt! www.jacc.org/doi/10.1016/... #CardioSky #MedSky
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial
www.jacc.org
July 28, 2025 at 7:42 PM
2° analysis of 1yr tirzepatide tx for obesity & #HFpEF in SUMMIT trial:
• Pts w/⬆️baseline BMI: greater ⬆️6MWD vs placebo
• Pts w/⬆️weight loss w/tx: greater ⬆️exercise capacity, sx burden
Incretin tx is an important part of HFpEF mgmt! www.jacc.org/doi/10.1016/... #CardioSky #MedSky
• Pts w/⬆️baseline BMI: greater ⬆️6MWD vs placebo
• Pts w/⬆️weight loss w/tx: greater ⬆️exercise capacity, sx burden
Incretin tx is an important part of HFpEF mgmt! www.jacc.org/doi/10.1016/... #CardioSky #MedSky
Early SHD detection saves lives, ⬇️costs, and ⬆️QoL, but underdx is common. Enter #AI to screen at scale! New in @nature.com: EchoNext, a deep ML ECG-based model:
- Accurately ID’d SHD
- Outperformed experts
- Performed across care settings, pt groups
link.med-iq.com/WNCVId
#CardioSky #MedSky
- Accurately ID’d SHD
- Outperformed experts
- Performed across care settings, pt groups
link.med-iq.com/WNCVId
#CardioSky #MedSky
Detecting structural heart disease from electrocardiograms using AI - Nature
EchoNext, a deep learning model for electrocardiograms trained and validated in diverse health systems, successfully detects many forms of structural heart disease, supporting the potential ...
www.nature.com
July 22, 2025 at 3:14 PM
Early SHD detection saves lives, ⬇️costs, and ⬆️QoL, but underdx is common. Enter #AI to screen at scale! New in @nature.com: EchoNext, a deep ML ECG-based model:
- Accurately ID’d SHD
- Outperformed experts
- Performed across care settings, pt groups
link.med-iq.com/WNCVId
#CardioSky #MedSky
- Accurately ID’d SHD
- Outperformed experts
- Performed across care settings, pt groups
link.med-iq.com/WNCVId
#CardioSky #MedSky
Hypertrophic cardiomyopathy (HCM) can be deceptively silent. Join this CME activity, designed to help more clinicians identify HCM early, confidently, and collaboratively through real-world patient journeys from symptom onset to diagnosis.
Earn credit link.med-iq.com/OmAZSa
@accintouch.bsky.social
Earn credit link.med-iq.com/OmAZSa
@accintouch.bsky.social
July 17, 2025 at 6:48 PM
Hypertrophic cardiomyopathy (HCM) can be deceptively silent. Join this CME activity, designed to help more clinicians identify HCM early, confidently, and collaboratively through real-world patient journeys from symptom onset to diagnosis.
Earn credit link.med-iq.com/OmAZSa
@accintouch.bsky.social
Earn credit link.med-iq.com/OmAZSa
@accintouch.bsky.social
From Ahmad Masri, MD et al in JACC Heart Failure: 1-yr FOREST-HCM OLE update
Ongoing efficacy of aficamten for #oHCM
• No HF events
• No new AF
• Low rate asx ⬇️LVEF (managed w/ dose reduction)
More at #ESC2025! @jaccjournals.bsky.social #CardioSky #MedSky
🔗 Full update: link.med-iq.com/MEKZHn
Ongoing efficacy of aficamten for #oHCM
• No HF events
• No new AF
• Low rate asx ⬇️LVEF (managed w/ dose reduction)
More at #ESC2025! @jaccjournals.bsky.social #CardioSky #MedSky
🔗 Full update: link.med-iq.com/MEKZHn
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
www.jacc.org
July 14, 2025 at 6:31 PM
From Ahmad Masri, MD et al in JACC Heart Failure: 1-yr FOREST-HCM OLE update
Ongoing efficacy of aficamten for #oHCM
• No HF events
• No new AF
• Low rate asx ⬇️LVEF (managed w/ dose reduction)
More at #ESC2025! @jaccjournals.bsky.social #CardioSky #MedSky
🔗 Full update: link.med-iq.com/MEKZHn
Ongoing efficacy of aficamten for #oHCM
• No HF events
• No new AF
• Low rate asx ⬇️LVEF (managed w/ dose reduction)
More at #ESC2025! @jaccjournals.bsky.social #CardioSky #MedSky
🔗 Full update: link.med-iq.com/MEKZHn
#Menopause transition (MT) raises sx & cardiometabolic Ds, increasing women's CVD risk but also offers a chance for early prevention. Check @jaccjournals.bsky.social for multidisciplinary guidance to lower MT CV risk! www.jacc.org/doi/10.1016/... #CardioSky #MedSky
Improving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife
www.jacc.org
July 7, 2025 at 4:57 PM
#Menopause transition (MT) raises sx & cardiometabolic Ds, increasing women's CVD risk but also offers a chance for early prevention. Check @jaccjournals.bsky.social for multidisciplinary guidance to lower MT CV risk! www.jacc.org/doi/10.1016/... #CardioSky #MedSky
Sports physical time! Timely article on professional liability risks w/SCA screening, return2play decisions, and counseling ↑risk athletes on participation choices & adequate rescue plans for potential CV events. www.sciencedirect.com/science/arti...
#CardioSky #MedSky
#CardioSky #MedSky
July 1, 2025 at 7:10 PM
Sports physical time! Timely article on professional liability risks w/SCA screening, return2play decisions, and counseling ↑risk athletes on participation choices & adequate rescue plans for potential CV events. www.sciencedirect.com/science/arti...
#CardioSky #MedSky
#CardioSky #MedSky
1/43 Welcome to this #CME #Skeetorial on transthyretin amyloid cardiomyopathy (ATTR-CM), including updates in treatment from ACC25, with cardiologist @mkittlesonmd.bsky.social.
Earn credit: link.med-iq.com/6h6qnR
#Cardiology #CardioEd #MedEd
Earn credit: link.med-iq.com/6h6qnR
#Cardiology #CardioEd #MedEd
June 30, 2025 at 5:49 PM
1/43 Welcome to this #CME #Skeetorial on transthyretin amyloid cardiomyopathy (ATTR-CM), including updates in treatment from ACC25, with cardiologist @mkittlesonmd.bsky.social.
Earn credit: link.med-iq.com/6h6qnR
#Cardiology #CardioEd #MedEd
Earn credit: link.med-iq.com/6h6qnR
#Cardiology #CardioEd #MedEd
New in @jama.com _current from @rohankhera.bsky.social et al: AI-enabled echo interpretation w/PanECHO. TL;DR: the validated tool accurately detects a range of CV conditions, even with low-quality POC imaging. Potential gamechanger! #CardioSky #MedSky
An #AI system that automatically interprets echocardiograms maintained high accuracy across geography and time from complete and limited studies.
https://ja.ma/4jYWBgI
https://ja.ma/4jYWBgI
June 23, 2025 at 8:03 PM
New in @jama.com _current from @rohankhera.bsky.social et al: AI-enabled echo interpretation w/PanECHO. TL;DR: the validated tool accurately detects a range of CV conditions, even with low-quality POC imaging. Potential gamechanger! #CardioSky #MedSky
ICYMI: an innovative approach to shrink blood clots uses shear forces to spin out RBCs!
This tiny device can shrink dangerous blood clots. It’s called the ‘milli-spinner’ and its invention was partly an accident…
June 10, 2025 at 1:39 PM
ICYMI: an innovative approach to shrink blood clots uses shear forces to spin out RBCs!
More guidance on CV risks of alcohol consumption, this time from @americanheart.bsky.social. An important point: be sure patients understand what “moderate” intake means, and what constitutes 1 drink! #CardioSky
The @americanheart.bsky.social just published their alcohol recommendations today which line up with the report by National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes)
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
June 9, 2025 at 9:27 PM
More guidance on CV risks of alcohol consumption, this time from @americanheart.bsky.social. An important point: be sure patients understand what “moderate” intake means, and what constitutes 1 drink! #CardioSky
New #cvACS guidelines take center stage in the June 10, 2025 issue of @jaccjournals.bsky.social
www.jacc.org/toc/jacc/cur....
More than just #ClinicalGuidelines, check out related expert perspectives, take-home messages, and more!
#CardioSky #MedSky
www.jacc.org/toc/jacc/cur....
More than just #ClinicalGuidelines, check out related expert perspectives, take-home messages, and more!
#CardioSky #MedSky
June 2, 2025 at 8:15 PM
New #cvACS guidelines take center stage in the June 10, 2025 issue of @jaccjournals.bsky.social
www.jacc.org/toc/jacc/cur....
More than just #ClinicalGuidelines, check out related expert perspectives, take-home messages, and more!
#CardioSky #MedSky
www.jacc.org/toc/jacc/cur....
More than just #ClinicalGuidelines, check out related expert perspectives, take-home messages, and more!
#CardioSky #MedSky
#HCM is often misdiagnosed. This complimentary, CME-accredited activity: spot subtle red flags in HCM, elevate your diagnostic confidence, & know when to escalate for early intervention. clinical.med-iq.com/activity/1936
#Cardiology #Echo #MedEd #CME #CardioSky #MedSky #HypertrophicCardiomyopathy
#Cardiology #Echo #MedEd #CME #CardioSky #MedSky #HypertrophicCardiomyopathy
May 30, 2025 at 5:52 PM
#HCM is often misdiagnosed. This complimentary, CME-accredited activity: spot subtle red flags in HCM, elevate your diagnostic confidence, & know when to escalate for early intervention. clinical.med-iq.com/activity/1936
#Cardiology #Echo #MedEd #CME #CardioSky #MedSky #HypertrophicCardiomyopathy
#Cardiology #Echo #MedEd #CME #CardioSky #MedSky #HypertrophicCardiomyopathy
1/11
Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights:
#LBCT by Marianna Fontana
#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM
#CardioSky #MedSky #Cardiology
Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights:
#LBCT by Marianna Fontana
#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM
#CardioSky #MedSky #Cardiology
May 25, 2025 at 2:59 PM
1/11
Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights:
#LBCT by Marianna Fontana
#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM
#CardioSky #MedSky #Cardiology
Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights:
#LBCT by Marianna Fontana
#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM
#CardioSky #MedSky #Cardiology
LBCT insights from SEQUOIA-HCM at #HeartFailure2025: #aficamten as effective in mildly symptomatic pts w/ #oHCM (NYHA class II/KCCQ-CSS ≥80) as in pts w/ moderate to severe sx. Now published in EHJ! doi.org/10.1093/eurheartj/ehaf364 #CardioSky #MedSky
May 19, 2025 at 2:46 PM
LBCT insights from SEQUOIA-HCM at #HeartFailure2025: #aficamten as effective in mildly symptomatic pts w/ #oHCM (NYHA class II/KCCQ-CSS ≥80) as in pts w/ moderate to severe sx. Now published in EHJ! doi.org/10.1093/eurheartj/ehaf364 #CardioSky #MedSky